Treatment of Acute Myeloblastic Leukaemia in a Patient with Bombay Blood Type: A Case Report

A 62-year-old female was admitted to our hospital with suspected acute leukaemia and after investigation we diagnosed acute myeloblastic leukaemia (AML-M1). The patient's blood type was found to be the very rare Bombay type and surveillance of her relatives showed the same blood type in her male cousin on her mother's side. Alongside chemotherapy the patient received 4000 ml of frozen Bombay-type red cells, 1400 ml of concentrated red cells in manitol adenine phosphate solutions and 360 units of type O concentrated platelets without marked effects. The anti-H antibody was initially at 128 dilution but for unknown reasons increased to 2048 dilution after remission of AML-M1. About 3 months after hospitalization the patient died of Cryptococcus neoformans pneumonia despite strict precautions against infection. Although AML-M1 is a common adult leukaemia and is chemosensitive to anti-leukaemic drugs, neither AML-M1 in a patient with Bombay-type red cells nor its treatment with chemotherapy and transfusion with type Oh frozen red cells have previously been reported.

[1]  Y. Koda,et al.  An Alu-mediated large deletion of the FUT2 gene in individuals with the ABO-Bombay phenotype , 1999, Human Genetics.

[2]  L. Svensson,et al.  Point Mutations and Deletion Responsible for the Bombay H null and the Reunion H weak Blood Groups , 1998, Vox Sanguinis.

[3]  Y. Koda,et al.  Missense mutation of FUT1 and deletion of FUT2 are responsible for Indian Bombay phenotype of ABO blood group system. , 1997, Biochemical and biophysical research communications.

[4]  M. Kaneko,et al.  Wide variety of point mutations in the H gene of Bombay and para-Bombay individuals that inactivate H enzyme. , 1997, Blood.

[5]  W. Flegel,et al.  Polymorphism of the h allele and the population frequency of sporadic nonfunctional alleles , 1997, Transfusion.

[6]  M. Grever,et al.  A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. , 1996, Blood.

[7]  O. Garson,et al.  A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. , 1996, Blood.

[8]  J. Lowe,et al.  Molecular basis for H blood group deficiency in Bombay (Oh) and para-Bombay individuals. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[9]  C. Tangen,et al.  A Southwest Oncology Group study , 1993 .

[10]  R. Foà,et al.  Has IL2 a role in the management of minimal residual disease for acute leukemia? , 1992, Leukemia.

[11]  M. Tomonaga,et al.  Randomized study of individualized induction therapy with or without VCR, and of maintenance of 4 or 12 courses in adult AML: JALSG-AML87. Japan Adult Leukemia Study Group (JALSG). , 1992, Leukemia.

[12]  J. Karp,et al.  Two-cycle timed-sequential chemotherapy for adult acute nonlymphocytic leukemia. , 1984, Blood.

[13]  M. Parvin,et al.  Immunological characteristics and clinical significance of anti‐H in the Ah phenotype , 1984, Transfusion.

[14]  J. Le Pendu,et al.  H-deficient blood groups of Reunion island. II. Differences between Indians (Bombay Phenotype) and whites (Reunion phenotype). , 1983, American journal of human genetics.

[15]  J. Lefante,et al.  Treatment of acute myelogenous leukemia: Influence of three induction regimens and maintenance with chemotherapy or BCG immunotherapy , 1982, Cancer.

[16]  P. Holland,et al.  The Clinical Significance of Anti‐H in an Individual with the Oh (Bombay) Phenotype , 1978, Transfusion.